PT2089024E - Combinação de inibidores de iap e inibidores de flt3 - Google Patents

Combinação de inibidores de iap e inibidores de flt3 Download PDF

Info

Publication number
PT2089024E
PT2089024E PT07868853T PT07868853T PT2089024E PT 2089024 E PT2089024 E PT 2089024E PT 07868853 T PT07868853 T PT 07868853T PT 07868853 T PT07868853 T PT 07868853T PT 2089024 E PT2089024 E PT 2089024E
Authority
PT
Portugal
Prior art keywords
combination
inhibitors
iap
flt3
active agents
Prior art date
Application number
PT07868853T
Other languages
English (en)
Inventor
James Douglas Griffin
Leigh Zawel
Original Assignee
Novartis Ag
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Dana Farber Cancer Inst Inc filed Critical Novartis Ag
Publication of PT2089024E publication Critical patent/PT2089024E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT07868853T 2006-11-28 2007-11-27 Combinação de inibidores de iap e inibidores de flt3 PT2089024E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US89108807P 2007-02-22 2007-02-22

Publications (1)

Publication Number Publication Date
PT2089024E true PT2089024E (pt) 2011-08-31

Family

ID=39386468

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07868853T PT2089024E (pt) 2006-11-28 2007-11-27 Combinação de inibidores de iap e inibidores de flt3

Country Status (20)

Country Link
US (1) US8492429B2 (pt)
EP (1) EP2089024B1 (pt)
JP (1) JP5394249B2 (pt)
KR (1) KR20090087094A (pt)
AT (1) ATE509629T1 (pt)
AU (1) AU2007325280B2 (pt)
BR (1) BRPI0719543A2 (pt)
CA (1) CA2670498A1 (pt)
CO (1) CO6210722A2 (pt)
EC (1) ECSP099472A (pt)
GT (1) GT200900142A (pt)
IL (1) IL198551A0 (pt)
MA (1) MA30966B1 (pt)
MX (1) MX2009005621A (pt)
NO (1) NO20092417L (pt)
PL (1) PL2089024T3 (pt)
PT (1) PT2089024E (pt)
RU (1) RU2456983C2 (pt)
TN (1) TN2009000206A1 (pt)
WO (1) WO2008067280A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2296650B1 (en) 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
CN102985439B9 (zh) 2010-02-12 2016-08-03 制药科学股份有限公司 Iap bir结构域结合化合物
AU2012315986A1 (en) 2011-09-30 2014-04-17 Srinivas Chunduru Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
EP3682873B1 (en) 2013-06-25 2024-06-12 The Walter and Eliza Hall Institute of Medical Research Smac mimetics for use in the treatment of persistent hiv infection
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
EA202191984A1 (ru) 2019-02-22 2021-11-19 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
WO2020171646A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
CA3134613A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1453661A1 (ru) * 1972-11-17 1989-10-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Противоопухолевое средство "продимин
BR0312408A (pt) 2002-07-02 2005-04-19 Novartis Ag Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap)
EP2065368A1 (en) * 2004-04-07 2009-06-03 Novartis Ag Inhibitors of IAP
EP1965865B1 (en) 2005-12-20 2018-05-16 Novartis AG Combination of an iap-inhibitor and a taxane
PE20110224A1 (es) * 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO

Also Published As

Publication number Publication date
US20100056467A1 (en) 2010-03-04
ECSP099472A (es) 2009-10-30
KR20090087094A (ko) 2009-08-14
RU2009124590A (ru) 2011-01-10
RU2456983C2 (ru) 2012-07-27
WO2008067280A3 (en) 2008-08-07
JP5394249B2 (ja) 2014-01-22
NO20092417L (no) 2009-08-25
PL2089024T3 (pl) 2011-10-31
US8492429B2 (en) 2013-07-23
MX2009005621A (es) 2009-06-12
MA30966B1 (fr) 2009-12-01
WO2008067280A2 (en) 2008-06-05
CO6210722A2 (es) 2010-10-20
AU2007325280B2 (en) 2011-03-10
ATE509629T1 (de) 2011-06-15
EP2089024B1 (en) 2011-05-18
CA2670498A1 (en) 2008-06-05
IL198551A0 (en) 2010-02-17
TN2009000206A1 (en) 2010-10-18
BRPI0719543A2 (pt) 2014-02-25
EP2089024A2 (en) 2009-08-19
JP2010511059A (ja) 2010-04-08
AU2007325280A1 (en) 2008-06-05
GT200900142A (es) 2010-06-24

Similar Documents

Publication Publication Date Title
IL198551A0 (en) Combination of iap inhibitors and flt3 inhibitors
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
ZA200701629B (en) Gyrase inhibitors and uses thereof
GEP20125691B (en) Compounds and compositions as protein kinase inhibitors
MX2009006877A (es) Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
EA200900691A1 (ru) Применение ингибиторов iap для лечения острого миелоидного лейкоза
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
HK1176318A1 (en) Injection device
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2007044180A3 (en) Improved toleration iron supplement compositions
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
MXPA05006408A (es) Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
MX2009005125A (es) Pirrolo[1,2-a]imidazoldiona efectiva en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos.
HUP0300576A2 (hu) Érkárosító hatású, osztott dózisú gyógyászati készítmény
WO2006091222A3 (en) Methods of treating and preventing severe acute respiratory syndrome (sars) with avr118
SI1830833T1 (sl) Kombinacija inhibitorja glicinskega transporterja GlyT in antipsihotika za zdravljenje simptomovshizofrenije in tudi njena priprava in njena uporaba